Senate Finance Chair Wyden continues fight over low pharma tax rates, this time with BMS

Sen. Ron Wyden (D-OR) isn’t done digging into the particularly low tax rates for pharma companies, and how their foreign ops can lower those bills.

In a three-page letter sent to Bristol Myers Squibb CEO Giovanni Caforio, Wyden sought more information on Bristol Myers’ international tax...

Click to view original post